Bone Therapeutics appointed a five-person scientific advisory board for guidance on developing induced pluripotent stem cell-derived mesenchymal stromal cell, the company said Oct. 12.
The iMSC platform will be used to develop cell and gene therapies to treat acute, life-threatening conditions. Leaders on the board have experience in therapeutics for a range of conditions including osteoarthritis, trauma and respiratory diseases.
The board comprises:
1 Massimo Dominici, MD, professor of medical oncology at University Hospital of Modena and Reggio Emilia in Italy
2. Frank Barry, PhD, professor of cellular therapy and regenerative medicine at National University of Ireland Galway
3. Robert Deans, PhD, chief scientific officer at genome engineering company Synthego
4. Richard Maziarz, MD, a researcher at Oregon Health & Science University in Portland
5. Patricia Rocco, MD, PhD, a professor at the Federal University of Rio de Janeiro in Brazil